ADVANCE infectious diseases pharmacy through collaboration, research and education and LEAD antimicrobial stewardship to OPTIMIZE the care of patients with infections in every practice setting

  • Home
  • About
  • News
  • Avibactam-Ceftazidime to FDA Ad Panel December 5th

Avibactam-Ceftazidime to FDA Ad Panel December 5th

03 Dec 2014 9:35 AM | Christopher McCoy

First came the wave of new agents aimed at resistant gram positive organisms, now the first novel serine beta-lactam/beta lactamase combination with expanded activity against multidrug resistant gram negative agents.The Anti-Infective Drug Advisory Committee (AIDAC) Meeting meets December 5, 2014 to discuss the new drug application (NDA) for ceftazidime-avibactam, submitted by Cerexa Inc., for the proposed indications of: Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, including Acute Pyelonephritis and Limited Use Indication: Aerobic Gram-negative Infections with Limited Treatment Options. 

Society of Infectious Diseases Pharmacists •  PO Box 1488, Warrenville, IL 60555
Proudly Managed by Affinity Strategies

Powered by Wild Apricot Membership Software